Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 1/2014

01-09-2014 | Case Report

A Case of Pediatric Acute Lymphoblastic Leukemia with Invasive Candidiasis: Short Review

Authors: S. P. Verma, B. Dubashi, P. Narayanan, D. Basu, T. K. Dutta, K. M. Dhanraj

Published in: Indian Journal of Hematology and Blood Transfusion | Special Issue 1/2014

Login to get access

Abstract

Mortality rate associated with invasive fungal infections is very high. Early suspicion for fungal infections is important during intensive chemotherapy for acute leukemia. Empirical treatment with antifungals amphotericin B or caspofungin should be started if patient is not responding to broad spectrum antibiotics and if expected duration of neutropenia is prolonged. We are reporting a 3 years old girl child with diagnosis of pre-B acute lymphoblastic leukemia who developed invasive candidiasis with typical clinical and radiological findings during induction chemotherapy. Candida non-albicans was isolated and she was treated with amphotericin B followed by caspofungin. Patient deteriorated after initial response and succumbed to death. Species identification and sensitivity pattern of fungus can help in selecting appropriate antifungal drug.
Literature
1.
go back to reference Gudlaugsson O, Gillespie S, Lee K, VandeBerg J, Hu J, Messer S et al (2003) Attributable mortality of nasociomial candidemia, revisited. Clin Infect Dis 37:1172–1177PubMedCrossRef Gudlaugsson O, Gillespie S, Lee K, VandeBerg J, Hu J, Messer S et al (2003) Attributable mortality of nasociomial candidemia, revisited. Clin Infect Dis 37:1172–1177PubMedCrossRef
2.
go back to reference Ostrosky-Zeichner L, Pappas PG (2006) Invasive candidiasis in the intensive care unit. Crit Care Med 34:63–875CrossRef Ostrosky-Zeichner L, Pappas PG (2006) Invasive candidiasis in the intensive care unit. Crit Care Med 34:63–875CrossRef
3.
go back to reference Fridkin SK (2005) The changing face of fungal infections in health care settings. Clin Infect Dis 41:1455PubMedCrossRef Fridkin SK (2005) The changing face of fungal infections in health care settings. Clin Infect Dis 41:1455PubMedCrossRef
4.
go back to reference Wenzel RP (1955) Nasocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 20(1531):4 Wenzel RP (1955) Nasocomial candidemia: risk factors and attributable mortality. Clin Infect Dis 20(1531):4
5.
go back to reference Zaoutis TE, Argon J, Chu J et al (2005) The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 41:1232–1239PubMedCrossRef Zaoutis TE, Argon J, Chu J et al (2005) The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 41:1232–1239PubMedCrossRef
6.
go back to reference Trick WE, Fridkin SK, Edwards JR et al (2002) Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin Infect Dis 35:627–630PubMedCrossRef Trick WE, Fridkin SK, Edwards JR et al (2002) Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999. Clin Infect Dis 35:627–630PubMedCrossRef
7.
go back to reference Bassetti M, Righi E, Costa A, Fasce R, Molinari MP, Rosso R et al (2006) Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 6:21PubMedCrossRefPubMedCentral Bassetti M, Righi E, Costa A, Fasce R, Molinari MP, Rosso R et al (2006) Epidemiological trends in nosocomial candidemia in intensive care. BMC Infect Dis 6:21PubMedCrossRefPubMedCentral
8.
go back to reference Garbino J, Kolarova L, Rohner P, Lew D, Pichna P, Pittet D (2002) Secular trends of candidemia over 12 years in adult patients at tertiary care hospital. Medicine (Baltimore) 81:4CrossRef Garbino J, Kolarova L, Rohner P, Lew D, Pichna P, Pittet D (2002) Secular trends of candidemia over 12 years in adult patients at tertiary care hospital. Medicine (Baltimore) 81:4CrossRef
10.
go back to reference Hart PD, Russell E Jr, Remington JS (1969) The compromised host and infection. II. Deep fungal infection. J Infect Dis 120:169PubMedCrossRef Hart PD, Russell E Jr, Remington JS (1969) The compromised host and infection. II. Deep fungal infection. J Infect Dis 120:169PubMedCrossRef
11.
go back to reference Wilson ML, Davis TE, Mirrett S et al (1993) Controlled comparison of the BACTEC high blood volume fungal medium, BACTEC Plus 26 aerobic blood culture bottle, and 10-milliliter isolator blood culture system for detection of fungemia and bacteremia. J Clin Microbiol 31:865PubMedPubMedCentral Wilson ML, Davis TE, Mirrett S et al (1993) Controlled comparison of the BACTEC high blood volume fungal medium, BACTEC Plus 26 aerobic blood culture bottle, and 10-milliliter isolator blood culture system for detection of fungemia and bacteremia. J Clin Microbiol 31:865PubMedPubMedCentral
12.
go back to reference Nucci M, Colombo AL, Silveira F et al (1998) Risk factors for death in patients with candidemia. Infect Control Hosp Epidemiol 19:846PubMedCrossRef Nucci M, Colombo AL, Silveira F et al (1998) Risk factors for death in patients with candidemia. Infect Control Hosp Epidemiol 19:846PubMedCrossRef
13.
go back to reference Morrell M, Fraser VJ, Kollef MH (2005) Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agent Chemother 49:3640CrossRef Morrell M, Fraser VJ, Kollef MH (2005) Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agent Chemother 49:3640CrossRef
14.
go back to reference Rex JH, Bennett JE, Sugar AM et al (1995) Intravascular catheter exchange and duration of candidemia. NIAID mycosis study group and the candidemia study group. Clin Infect Dis 21:994PubMedCrossRef Rex JH, Bennett JE, Sugar AM et al (1995) Intravascular catheter exchange and duration of candidemia. NIAID mycosis study group and the candidemia study group. Clin Infect Dis 21:994PubMedCrossRef
15.
go back to reference Blyth CC, Hale K, Palasanthiram P, et al. (2010) Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infection. Cochrane Database Syst Rev CD006343 Blyth CC, Hale K, Palasanthiram P, et al. (2010) Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infection. Cochrane Database Syst Rev CD006343
16.
go back to reference Fidel PL Jr, Vazquez JA, Sobel JD (1999) Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to candida albicans. Clin Microbiol Rev 12:80PubMedPubMedCentral Fidel PL Jr, Vazquez JA, Sobel JD (1999) Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to candida albicans. Clin Microbiol Rev 12:80PubMedPubMedCentral
17.
go back to reference Zaoutis T, Lehrnbecher T, Groll AH et al (2009) Safety experience with caspofungin in pediatric patients. Pediatr Infect Dis J 28:1132PubMedCrossRef Zaoutis T, Lehrnbecher T, Groll AH et al (2009) Safety experience with caspofungin in pediatric patients. Pediatr Infect Dis J 28:1132PubMedCrossRef
Metadata
Title
A Case of Pediatric Acute Lymphoblastic Leukemia with Invasive Candidiasis: Short Review
Authors
S. P. Verma
B. Dubashi
P. Narayanan
D. Basu
T. K. Dutta
K. M. Dhanraj
Publication date
01-09-2014
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue Special Issue 1/2014
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-013-0274-z

Other articles of this Special Issue 1/2014

Indian Journal of Hematology and Blood Transfusion 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine